George Clinical is a leading provider of oncology trial, scientific, and operational solutions throughout the Asia-Pacific, USA and Europe.
As a leader in the design and delivery of care-based, oncology research, George Clinical has access to significant global investigator networks, experienced project teams, oncology experts, and scientific leaders to design and deliver oncology trials, with the latest immunotherapies, to the highest scientific standards. By accessing some of the world’s most experienced medical, scientific and operational teams in oncology research, George Clinical is uniquely placed to meet the increasingly complex and specialized demands of modern oncology research, and thus demonstrates product value in terms of clinical effectiveness, specialized cohorts and tolerability.
Exceptional medical, scientific and operational expertise makes George Clinical an ideal partner for clinical trials throughout North America, Europe and the Asia-Pacific.
George Clinical has extensive experience in all phases of oncology programs including, MTD, early Phase I, II and III and late-phase trials, health economics and outcomes research. Our full services team is comprised of scientific leaders, doctors, nurses, biostatisticians and trial management professionals that work together to ensure timely delivery of quality trial data on time and on budget.
George Clinical offers a unique combination of scientific leadership and operational capabilities to design and deliver studies for sponsors, no matter the complexity. George Clinical offers:
George Clinical’s extensive experience in oncology trials provides sponsors with the confidence that their oncology trial will be delivered on time, on budget and to the highest scientific standards.
Our clinical trial services in oncology clinical trials include:
Lee Schwartzberg, MD, FACP, is a medical oncologist and hematologist, senior partner and medical director at the community-based private practice West Cancer Center. Dr. Schwartzberg is founding Editor-in-Chief for Oncologystat.com and was the founding Editor-in-Chief for Community Oncology Journal. He serves as the Division Chief of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center. Dr. Schwartzberg also serves on the Board of Directors for the National Comprehensive Cancer Network. His research interests include breast cancer, supportive care and developmental therapeutics, having published over 110 peer-reviewed publications.
Dr. Ari VanderWalde is an internationally-recognized cancer researcher, Dr. VanderWalde holds a dual appointment with the University of Tennessee Health Science Center as Associate Vice Chancellor of Research and Assistant Professor, Hematology/Oncology.
Dr. VanderWalde previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing US global development of talimogene laherparepvec, a novel viral-based immunotherapeutic that has shown efficacy in late-stage clinical trials in melanoma. As an expert in melanoma, Dr. VanderWalde has collaborated with some of the nation’s thought leaders and participated on advisory boards with top experts in the field.
A native of Memphis, TN, Dr. Chandler attended Christian Brothers University where he received a degree in electrical engineering. He went on to pursue a career in medicine and attended the University Of Tennessee School Of Medicine, receiving his Medical Degree in 2003. Dr. Chandler also completed his postdoctoral training in Internal Medicine and Pediatrics at the University Of Tennessee School Of Medicine. During his medical rotations he had the opportunity to meet and work with Drs. Lee Schwartzberg and Arnel Pallera. Dr. Chandler went on to receive a fellowship in Medical Oncology/Hematology at The Ohio State University Medical Center in Columbus where he concentrated on leukemia research and immunology. With a strong research interest, Dr. Chandler has co-authored several articles appearing in peer-reviewed publications and presented nationally.